Status:
RECRUITING
Pharmacogenetic Supported Prescribing in Kids
Lead Sponsor:
University of Calgary
Conditions:
Mental Health Impairment
Eligibility:
All Genders
6-24 years
Phase:
NA
Brief Summary
Implementation of pharmacogenetic testing for children and adolescents aged 6-24 who are starting or changing psychiatric medication.
Detailed Description
Children with moderate to severe mental health conditions (e.g. depression, anxiety, OCD) or neurodevelopmental disorders (e.g., autism spectrum disorders, ADHD) are frequently prescribed medications ...
Eligibility Criteria
Inclusion
- Medical records available
- The initiation, change, dose adjustment, or augmentation of psychiatric medication(s) is indicated
- Treating psychiatrist, family physician, or pediatrician licensed in Alberta, British Columbia, Saskatchewan, or Manitoba requests pharmacogenetic testing
Exclusion
- Medically unstable or lacking capacity to provided informed consent
- Unwillingness of child to provide saliva sample for genetic analysis
- History of liver or bone marrow (hematopoietic cell) transplant
Key Trial Info
Start Date :
January 18 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2025
Estimated Enrollment :
6000 Patients enrolled
Trial Details
Trial ID
NCT04797364
Start Date
January 18 2021
End Date
July 1 2025
Last Update
May 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Calgary
Calgary, Alberta, Canada, T2N 4N1